These findings would be supported by the BC prevention studies of tamoxifen34 and aromatase inhibitors35,36 versus placebo, which have reported a significant reduction in ER-positive BC (both invasive and DCIS) but no significant reduction in ER-negative BC. This evidence concerns the gene CYP19A1 and ductal breast carcinoma in situ.